Level of influenza virus strain antibodies in healthy vaccinated people at the end of the COVID-19 pandemic
- Authors: Iushkova S.V.1, Kostinov M.P.1,2, Gladkova L.S.3,4, Kameleva A.A.3,5, Kachnova A.S.3, Kostinova A.M.1,3, Solovyeva I.L.6, Andreeva N.P.7, Dagil Y.A.4, Nastaeva N.Y.8, Kryukova N.O.9, Loktionova M.N.1,2,10
-
Affiliations:
- I.M. Sechenov First State Medical University (Sechenov University)
- I. Mechnikov Research Institute of Vaccines and Sera
- D.D. Pletnev City Clinical Hospital of the Moscow City Health Department
- National Research Center “Institute of Immunology” of the Federal Medical-Biological Agency of Russia
- Russian University of Peoples’ Friendship named after Patrice Lumumba
- Ulyanovsk State University
- Chuvash State University
- Novorossiysk Clinical Center of Federal Medical Biological Agency
- Pirogov Russian National Research Medical University (Pirogov Medical University)
- Central Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
- Issue: Vol 14, No 1 (2024)
- Pages: 57-65
- Section: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/2220-7619/article/view/256766
- DOI: https://doi.org/10.15789/2220-7619-LOI-17598
- ID: 256766
Cite item
Full Text
Abstract
Introduction. Abnormally low global influenza detection rates were observed at the peak of ongoing COVID-19 infection. In the 2021–2022 season, influenza resumed circulation, and in December 2022 its incidence rate returned to the 2015–2016 season levels, which exceeded the highest value recorded in 2018 worldwide. There is a need to assess changes in pattern of population immunity after influenza vaccination during the global COVID-19 pandemic. The study was aimed at analyzing level of vaccine influenza virus strain antibodies in healthy people formed during the COVID-19 pandemic.
Materials and methods. A total of 123 healthy volunteers immunized with influenza quadrivalent inactivated subunit adjuvanted vaccine and 47 unimmunized volunteers were enrolled in the study. Influenza virus strains antibodies were assessed by performing a hemagglutination inhibition (HI) test one month after vaccination.
Results. A significantly increased seroprotection rate (SPR) (p < 0.05) was show in main group that reached 78.9% against the A/Victoria/2570/2019(H1N1)pdm09 strain, 94.3% — against A/H3N2/Darwin strain /9/2021, 69.1% — against B/Phuket/3073/13 strain and 48.8% — against B/Austria/1359417/2021 strain one month after vaccination. The GMT ratio to influenza A(H1N1), B (Victoria) and B (Yamagata) viruses exceeded the required minimum value (p < 0.05) and comprised 4.1 (CI 3.68–4.54), 3.80 (CI 3.33–4.33) and 4.76 (CI 3.87–5.47), respectively. The post-vaccination GMT ratio to influenza A(H3N2) virus was 2.45, which is lower than the required level of 2.50 (p < 0.05). The seroconversion rate (SCR) for strains A/Victoria/2570/2019(H1N1)pdm09, B/Phuket/3073/2013 and B/Austria/1359417/2021 was 56.1%, 50.4% and 51.2%, respectively. The SCR of the influenza A(H3N2) virus like GMT ratio was minimal among the four strains (p < 0.05) and comprised 38.2%.
Conclusion. The vaccine-related immunogenic activity met the requirements for inactivated seasonal influenza vaccines by at least one criterion.
Full Text
##article.viewOnOriginalSite##About the authors
S. V. Iushkova
I.M. Sechenov First State Medical University (Sechenov University)
Author for correspondence.
Email: sofia-b@bk.ru
PhD Student, Department of Epidemiology and Modern Vaccination Technologies of Professional Education Institute
Russian Federation, MoscowM. P. Kostinov
I.M. Sechenov First State Medical University (Sechenov University); I. Mechnikov Research Institute of Vaccines and Sera
Email: sofia-b@bk.ru
Honored Scientist of the Russian Federation, RAS Corresponding Member, DSc (Medicine), Professor, Head of the Department of Epidemiology and Modern Vaccination Technologies, Head of the Laboratory for Vaccine Prevention and Immunotherapy of Allergic Diseases
Russian Federation, Moscow; MoscowL. S. Gladkova
D.D. Pletnev City Clinical Hospital of the Moscow City Health Department; National Research Center “Institute of Immunology” of the Federal Medical-Biological Agency of Russia
Email: sofia-b@bk.ru
PhD (Medicine), Deputy Head Physician for Sanitary and Epidemiology, Associate Professor, Department of Epidemiology and Social Hygiene
Russian Federation, Moscow; MoscowA. A. Kameleva
D.D. Pletnev City Clinical Hospital of the Moscow City Health Department; Russian University of Peoples’ Friendship named after Patrice Lumumba
Email: sofia-b@bk.ru
PhD (Medicine), Allergist-Immunologist, Consultative and Diagnostic Department, Assistant Professor of the Department of Clinical Immunology, Allergy, and Adaptation of the Faculty of Continuous Medical Education of the Medical Institute
Russian Federation, Moscow; MoscowA. S. Kachnova
D.D. Pletnev City Clinical Hospital of the Moscow City Health Department
Email: sofia-b@bk.ru
Allergist-Immunologist, Consultative and Diagnostic Department
Russian Federation, MoscowA. M. Kostinova
I.M. Sechenov First State Medical University (Sechenov University); D.D. Pletnev City Clinical Hospital of the Moscow City Health Department
Email: sofia-b@bk.ru
Assistant Professor, Department of Epidemiology and Modern Vaccination Technologies, Allergist-Immunologist
Russian Federation, Moscow; MoscowI. L. Solovyeva
Ulyanovsk State University
Email: sofia-b@bk.ru
DSc (Medicine), Professor, Head of the Department of Pediatrics, faculty of medicine named after T.Z. Biktimirov Institute of Medicine, Ecology and Physical Education
Russian Federation, UlyanovskN. P. Andreeva
Chuvash State University
Email: sofia-b@bk.ru
PhD (Medicine), Associate Professor, Department of Healthcare Organization and Information Technologies in Medicine
Russian Federation, CheboksaryYu. A. Dagil
National Research Center “Institute of Immunology” of the Federal Medical-Biological Agency of Russia
Email: sofia-b@bk.ru
PhD (Biology), Researcher
Russian Federation, MoscowN. Yu. Nastaeva
Novorossiysk Clinical Center of Federal Medical Biological Agency
Email: sofia-b@bk.ru
Epidemiologist
Russian Federation, NovorossiyskN. O. Kryukova
Pirogov Russian National Research Medical University (Pirogov Medical University)
Email: sofia-b@bk.ru
Assistant Professor, Department of Hospital Therapy, Pediatrics Faculty
Russian Federation, MoscowM. N. Loktionova
I.M. Sechenov First State Medical University (Sechenov University); I. Mechnikov Research Institute of Vaccines and Sera; Central Research Institute of Epidemiology of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
Email: sofia-b@bk.ru
PhD (Medicine), Associate Professor, Department of Epidemiology and Modern Vaccination Technologies, Senior Researcher, Laboratory of Epidemiology, Senior Researcher, Laboratory of Epidemiology of Natural Focal Infections
Russian Federation, Moscow; Moscow; MoscowReferences
- Бузицкая Ж.В., Попов А.Б., Романовская-Романько Е.А., Сергеева М.В., Варюшина Е.А., Ерофеева М.К., Стукова М.А., Лиознов Д.А. Оценка гуморального иммунного ответа у детей при иммунизации разными типами инактивированных гриппозных вакцин в сезон 2019–2020 года // Медицинская иммунология. 2023. Т. 25, № 4. С. 751–758. [Buzitskaya Zh.V., Popov A.B., Romanovskaya-Romanko E.A., Sergeeva M.V., Varyushina E.A., Erofeeva M.K., Stukova M.A., Lioznov D.A. Assessment of the humoral immune response in children after immunization with different types of inactivated influenza vaccines in the 2019–2020 season. Meditsinskaya immunologiya = Medical Immunology (Russia), 2023, vol. 25, no. 4, pp. 751–758. (In Russ.)] doi: 10.15789/1563-0625-AOT-2737
- Еженедельный бюллетень по гриппу. СПб.: ФГБУ «Научно-исследовательский институт гриппа имени А.А. Смородинцева» Министерства здравоохранения Российской Федерации. [Weekly flu bulletin. St. Petersburg: Smorodintsev Research Institute of Influenza. (In Russ.)] URL: https://www.influenza.spb.ru/system/epidemic_situation/laboratory_diagnostics (10.01.2024)
- Костинов М.П. Вакцинация взрослых — от стратегии к тактике. Руководство для врачей. М.: Группа МДВ, 2020. 248 c. [Kostinov M.P. Adult vaccination: from strategy to tactics. Guide for physicians. Moscow: MDV Group, 2020. 248 p. (In Russ.)]
- Кривицкая В.З., Кузнецова Е.В., Майорова В.Г., Петрова Е.Р., Соминина А.А., Даниленко Д.М. Влияние вакцинации против гриппа на уровень специфического гуморального иммунитета здоровых лиц // Инфекция и иммунитет. 2022. Т. 12, № 1. C. 127–141. [Krivitskaya V.Z., Kuznecova E.V., Maiorova V.G., Petrova E.R., Sominina A.A., Danilenko D.M. Influenza vaccination influencing level of specific humoral immunity in healthy individuals. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2022, vol. 12, no. 1, pp. 127–141. (In Russ.)] doi: 10.15789/2220-7619-IVI-1750
- О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2022 году: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2023. 195 c. [On the state of sanitary and epidemiological welfare of the population in the Russian Federation in 2022: State report. Moscow: Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing, 2023. 195 p. (In Russ.)]
- Basu I., Agarwal M., Shah V., Shukla V., Naik S., Supe P.D., Srivastava M.K., Giriraja K.V., Pinjar P., Mishra P.K., Joshi S., Vijayakumar R., van de Witte S. Immunogenicity and safety of two quadrivalent influenza vaccines in healthy adult and elderly participants in India — a phase III, active-controlled, randomized clinical study. Hum. Vaccin. Immunother., 2022, vol. 18, no. 1, pp. 1–10. doi: 10.1080/21645515.2021.1885278
- Gomez G.B., Mahé C., Chaves S.S. Uncertain effects of the pandemic on respiratory viruses. Science, 2021, vol. 372, iss. 6546, pp. 1043–1044. doi: 10.1126/science.abh3986
- Olsen S.J., Azziz-Baumgartner E., Budd A.P., Brammer L., Sullivan S., Pineda R.F., Cohen C., Fry A.M. Decreased influenza activity during the COVID-19 pandemic-United States, Australia, Chile, and South Africa, 2020. Am. J. Transplant., 2020, vol. 20, no. 12, pp. 3681–3685. doi: 10.1111/ajt.16381
- Sullivan S.G., Carlson S., Cheng A.C., Chilver M.B., Dwyer D.E., Irwin M., Kok J., Macartney K., MacLachlan J., Minney-Smith C., Smith D., Stocks N., Taylor J., Barr I.G. Where has all the influenza gone? The impact of COVID-19 on the circulation of influenza and other respiratory viruses, Australia, March to September 2020. Euro Surveill., 2020, vol. 25, no. 47: pii 2001847. doi: 10.2807/1560-7917.ES.2020.25.47.2001847
- Quan C., Zhang Z., Ding G., Sun F., Zhao H., Liu Q., Ma C., Wang J., Wang L., Zhao W., He J., Wang Y., He Q., Carr M.J., Wang D., Xiao Q., Shi W. Seroprevalence of influenza viruses in Shandong, Northern China during the COVID-19 pandemic. Front. Med., 2022, vol. 16, no. 6, pp. 984–990. doi: 10.1007/s11684-022-0930-5
- WHO. Influenza laboratory surveillance information. Virus detections by subtype reported to FluNet. URL: https://app.powerbi.com/view?r=eyJrIjoiZTkyODcyOTEtZjA5YS00ZmI0LWFkZGUtODIxNGI5OTE3YjM0IiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9 (10.01.2024)
- WHO. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. 2023. URL: https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic (10.01.2024)
